[
  {
    "ts": null,
    "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
    "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752490011,
      "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
      "id": 135926879,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192786673/image_2192786673.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05"
    }
  },
  {
    "ts": null,
    "headline": "Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence",
    "summary": "The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Oce",
    "url": "https://finnhub.io/api/news?id=455e0a4fde561191a601c0050128fc25e7355953748963090f8d57f3eed6d094",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752485340,
      "headline": "Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence",
      "id": 135921172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Oce",
      "url": "https://finnhub.io/api/news?id=455e0a4fde561191a601c0050128fc25e7355953748963090f8d57f3eed6d094"
    }
  },
  {
    "ts": null,
    "headline": "Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments",
    "summary": "Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to surpass 1 billion people globally by 2050, the demand for innovative interventions like anti-VEGF therapies is surging. However, the high cost of treatments remains a challenge, particularly in developing regions. Companies such as Regeneron, Roche, and Bayer are driving advances in treatment technolog",
    "url": "https://finnhub.io/api/news?id=0f58deac66f059a3b51c97aaa67972b48efd953dc77341188a6701d67cac39f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752484800,
      "headline": "Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments",
      "id": 135921173,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to surpass 1 billion people globally by 2050, the demand for innovative interventions like anti-VEGF therapies is surging. However, the high cost of treatments remains a challenge, particularly in developing regions. Companies such as Regeneron, Roche, and Bayer are driving advances in treatment technolog",
      "url": "https://finnhub.io/api/news?id=0f58deac66f059a3b51c97aaa67972b48efd953dc77341188a6701d67cac39f7"
    }
  },
  {
    "ts": null,
    "headline": "Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape",
    "summary": "The global wet age-related macular degeneration (AMD) market is expanding rapidly due to factors like an aging population, advancements in treatment options, and increased awareness. A leading cause of vision loss in people over 50, wet AMD is primarily treated with anti-VEGF therapies, which dominate the market. Innovations like cell and gene therapy, early detection technologies like OCT, and personalized medicine are shaping the market's future. However, challenges such as high treatment cost",
    "url": "https://finnhub.io/api/news?id=682b9a992e8eb83b4b951f6a4cc5c1cda1b7e2da807e447ca9d5ed47eefedb35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752482820,
      "headline": "Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape",
      "id": 135921175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The global wet age-related macular degeneration (AMD) market is expanding rapidly due to factors like an aging population, advancements in treatment options, and increased awareness. A leading cause of vision loss in people over 50, wet AMD is primarily treated with anti-VEGF therapies, which dominate the market. Innovations like cell and gene therapy, early detection technologies like OCT, and personalized medicine are shaping the market's future. However, challenges such as high treatment cost",
      "url": "https://finnhub.io/api/news?id=682b9a992e8eb83b4b951f6a4cc5c1cda1b7e2da807e447ca9d5ed47eefedb35"
    }
  }
]